To target or not to target APRIL in systemic lupus erythematosus: that is the question!

Abstract

Among the cytokines that regulate B-cell homeostasis are the TNF-like ligands B-lymphocyte stimulator (BLyS; also B-cell activation factor) and a proliferation-inducing ligand (APRIL). BLyS and APRIL share two receptors; that is, B-cell maturation antigen and transmembrane activator and CAML interactor. Therapeutic approaches using biologics are limited for treatment of lupus patients. One previously approved drug is belimumab, which antagonizes the B-cell stimulator BLyS. Atacicept, another biologic inhibiting BLyS and APRIL, was terminated for serious adverse events--raising the question of whether APRIL should be neutralized in autoimmune diseases.

• Authors: Jacques Morel, Michael Hahne
• Journal: Arthritis research & therapy (Arthritis Res Ther) Vol. 15 Issue 1 Pg. 107 (Feb 25 2013) ISSN: 1478-6362 [Electronic] England
• PMID: 23438039 (Publication Type: Editorial, Comment)

Chemical References

• Biomarkers
• TNFSF13 protein, human
• Tumor Necrosis Factor Ligand Superfamily Member 13

Topics

• Biomarkers (blood)
• Female
• Humans
• Kidney (metabolism)
• Lupus Nephritis (blood)
• Male
• Tumor Necrosis Factor Ligand Superfamily Member 13 (blood)